Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,085
archived clinical trials in
Cervical Cancer

Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary
Status: Enrolling
Updated:  1/9/2018
Spartanburg Medical Center
mi
from
Spartanburg, SC
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary
Status: Enrolling
Updated: 1/9/2018
Spartanburg Medical Center
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary
Status: Enrolling
Updated:  1/9/2018
Vanderbilt University/Ingram Cancer Center
mi
from
Nashville, TN
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary
Status: Enrolling
Updated: 1/9/2018
Vanderbilt University/Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary
Status: Enrolling
Updated:  1/9/2018
UT Southwestern/Simmons Cancer Center-Dallas
mi
from
Dallas, TX
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary
Status: Enrolling
Updated: 1/9/2018
UT Southwestern/Simmons Cancer Center-Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary
Status: Enrolling
Updated:  1/9/2018
University of Texas Medical Branch
mi
from
Galveston, TX
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary
Status: Enrolling
Updated: 1/9/2018
University of Texas Medical Branch
mi
from
Galveston, TX
Click here to add this to my saved trials
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary
Status: Enrolling
Updated:  1/9/2018
Methodist Hospital System
mi
from
Houston, TX
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary
Status: Enrolling
Updated: 1/9/2018
Methodist Hospital System
mi
from
Houston, TX
Click here to add this to my saved trials
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary
Status: Enrolling
Updated:  1/9/2018
University of Vermont Medical Center
mi
from
Burlington, VT
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary
Status: Enrolling
Updated: 1/9/2018
University of Vermont Medical Center
mi
from
Burlington, VT
Click here to add this to my saved trials
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary
Status: Enrolling
Updated:  1/9/2018
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary
Status: Enrolling
Updated: 1/9/2018
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary
Status: Enrolling
Updated:  1/9/2018
Rockwood Cancer Treatment Center-DHEC-Downtown
mi
from
Spokane, WA
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary
Status: Enrolling
Updated: 1/9/2018
Rockwood Cancer Treatment Center-DHEC-Downtown
mi
from
Spokane, WA
Click here to add this to my saved trials
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary
Status: Enrolling
Updated:  1/9/2018
MultiCare Tacoma General Hospital
mi
from
Tacoma, WA
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary
Status: Enrolling
Updated: 1/9/2018
MultiCare Tacoma General Hospital
mi
from
Tacoma, WA
Click here to add this to my saved trials
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary
Status: Enrolling
Updated:  1/9/2018
Wenatchee Valley Hospital and Clinics
mi
from
Wenatchee, WA
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary
Status: Enrolling
Updated: 1/9/2018
Wenatchee Valley Hospital and Clinics
mi
from
Wenatchee, WA
Click here to add this to my saved trials
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary
Status: Enrolling
Updated:  1/9/2018
Gundersen Lutheran Medical Center
mi
from
La Crosse, WI
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary
Status: Enrolling
Updated: 1/9/2018
Gundersen Lutheran Medical Center
mi
from
La Crosse, WI
Click here to add this to my saved trials
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary
Status: Enrolling
Updated:  1/9/2018
ProHealth D N Greenwald Center
mi
from
Mukwonago, WI
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary
Status: Enrolling
Updated: 1/9/2018
ProHealth D N Greenwald Center
mi
from
Mukwonago, WI
Click here to add this to my saved trials
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary
Status: Enrolling
Updated:  1/9/2018
ProHealth Oconomowoc Memorial Hospital
mi
from
Oconomowoc, WI
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary
Status: Enrolling
Updated: 1/9/2018
ProHealth Oconomowoc Memorial Hospital
mi
from
Oconomowoc, WI
Click here to add this to my saved trials
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary
Status: Enrolling
Updated:  1/9/2018
Vince Lombardi Cancer Clinic - Two Rivers
mi
from
Two Rivers, WI
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary
Status: Enrolling
Updated: 1/9/2018
Vince Lombardi Cancer Clinic - Two Rivers
mi
from
Two Rivers, WI
Click here to add this to my saved trials
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary
Status: Enrolling
Updated:  1/9/2018
ProHealth Waukesha Memorial Hospital
mi
from
Waukesha, WI
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary
Status: Enrolling
Updated: 1/9/2018
ProHealth Waukesha Memorial Hospital
mi
from
Waukesha, WI
Click here to add this to my saved trials
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary
Status: Enrolling
Updated:  1/9/2018
Aurora West Allis Medical Center
mi
from
West Allis, WI
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary
Status: Enrolling
Updated: 1/9/2018
Aurora West Allis Medical Center
mi
from
West Allis, WI
Click here to add this to my saved trials
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary
Status: Enrolling
Updated:  1/9/2018
Keimyung University-Dongsan Medical Center
mi
from
Jung-Ku,
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary
Status: Enrolling
Updated: 1/9/2018
Keimyung University-Dongsan Medical Center
mi
from
Jung-Ku,
Click here to add this to my saved trials
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary
Status: Enrolling
Updated:  1/9/2018
MedStar Washington Hospital Center
mi
from
Washington,
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary
Status: Enrolling
Updated: 1/9/2018
MedStar Washington Hospital Center
mi
from
Washington,
Click here to add this to my saved trials
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary
Status: Enrolling
Updated:  1/9/2018
Shawnee Mission Medical Center-KCCC
mi
from
Shawnee Mission, KA
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary
Status: Enrolling
Updated: 1/9/2018
Shawnee Mission Medical Center-KCCC
mi
from
Shawnee Mission, KA
Click here to add this to my saved trials
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary
Status: Enrolling
Updated:  1/9/2018
Jersey Shore Medical Center
mi
from
Neptune, NJ
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary
Status: Enrolling
Updated: 1/9/2018
Jersey Shore Medical Center
mi
from
Neptune, NJ
Click here to add this to my saved trials
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  1/9/2018
The Hartford Hospital
mi
from
Hartford, CT
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 1/9/2018
The Hartford Hospital
mi
from
Hartford, CT
Click here to add this to my saved trials
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  1/9/2018
The Hospital of Central Connecticut
mi
from
New Britain, CT
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 1/9/2018
The Hospital of Central Connecticut
mi
from
New Britain, CT
Click here to add this to my saved trials
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  1/9/2018
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 1/9/2018
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  1/9/2018
Sudarshan K Sharma MD Limted-Gynecologic Oncology
mi
from
Hinsdale, IL
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 1/9/2018
Sudarshan K Sharma MD Limted-Gynecologic Oncology
mi
from
Hinsdale, IL
Click here to add this to my saved trials
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  1/9/2018
Iowa Lutheran Hospital
mi
from
Des Moines, IA
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 1/9/2018
Iowa Lutheran Hospital
mi
from
Des Moines, IA
Click here to add this to my saved trials
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  1/9/2018
Iowa Methodist Medical Center
mi
from
Des Moines, IA
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 1/9/2018
Iowa Methodist Medical Center
mi
from
Des Moines, IA
Click here to add this to my saved trials
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  1/9/2018
Mercy Medical Center - Des Moines
mi
from
Des Moines, IA
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 1/9/2018
Mercy Medical Center - Des Moines
mi
from
Des Moines, IA
Click here to add this to my saved trials
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  1/9/2018
Saint Joseph Mercy Hospital
mi
from
Ann Arbor, MI
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 1/9/2018
Saint Joseph Mercy Hospital
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  1/9/2018
Saint John Hospital and Medical Center
mi
from
Detroit, MI
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 1/9/2018
Saint John Hospital and Medical Center
mi
from
Detroit, MI
Click here to add this to my saved trials
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  1/9/2018
Hurley Medical Center
mi
from
Flint, MI
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 1/9/2018
Hurley Medical Center
mi
from
Flint, MI
Click here to add this to my saved trials
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  1/9/2018
Genesys Regional Medical Center
mi
from
Grand Blanc, MI
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 1/9/2018
Genesys Regional Medical Center
mi
from
Grand Blanc, MI
Click here to add this to my saved trials
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  1/9/2018
Allegiance Health
mi
from
Jackson, MI
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 1/9/2018
Allegiance Health
mi
from
Jackson, MI
Click here to add this to my saved trials
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  1/9/2018
Sparrow Hospital
mi
from
Lansing, MI
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 1/9/2018
Sparrow Hospital
mi
from
Lansing, MI
Click here to add this to my saved trials
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  1/9/2018
Saint Mary's of Michigan
mi
from
Saginaw, MI
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 1/9/2018
Saint Mary's of Michigan
mi
from
Saginaw, MI
Click here to add this to my saved trials
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  1/9/2018
University of Mississippi Medical Center
mi
from
Jackson, MS
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 1/9/2018
University of Mississippi Medical Center
mi
from
Jackson, MS
Click here to add this to my saved trials
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  1/9/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 1/9/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  1/9/2018
Mercy Hospital Springfield
mi
from
Springfield, MO
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 1/9/2018
Mercy Hospital Springfield
mi
from
Springfield, MO
Click here to add this to my saved trials
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  1/9/2018
Nebraska Methodist Hospital
mi
from
Omaha, NE
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 1/9/2018
Nebraska Methodist Hospital
mi
from
Omaha, NE
Click here to add this to my saved trials
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  1/9/2018
Case Western Reserve Univ
mi
from
Cleveland, OH
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 1/9/2018
Case Western Reserve Univ
mi
from
Cleveland, OH
Click here to add this to my saved trials
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  1/9/2018
Riverside Methodist Hospital
mi
from
Columbus, OH
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 1/9/2018
Riverside Methodist Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  1/9/2018
Lake University Ireland Cancer Center
mi
from
Mentor, OH
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 1/9/2018
Lake University Ireland Cancer Center
mi
from
Mentor, OH
Click here to add this to my saved trials
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  1/9/2018
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 1/9/2018
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  1/9/2018
Abington Memorial Hospital
mi
from
Abington, PA
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 1/9/2018
Abington Memorial Hospital
mi
from
Abington, PA
Click here to add this to my saved trials
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  1/9/2018
AnMedical Health Cancer Center
mi
from
Anderson, SC
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 1/9/2018
AnMedical Health Cancer Center
mi
from
Anderson, SC
Click here to add this to my saved trials
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  1/9/2018
Memorial Hermann Texas Medical Center
mi
from
Houston, TX
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 1/9/2018
Memorial Hermann Texas Medical Center
mi
from
Houston, TX
Click here to add this to my saved trials
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  1/9/2018
Smilow Cancer Hospital Care Center at Saint Francis
mi
from
Hartford, CT
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 1/9/2018
Smilow Cancer Hospital Care Center at Saint Francis
mi
from
Hartford, CT
Click here to add this to my saved trials
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  1/9/2018
Florida Hospital Orlando
mi
from
Orlando, FL
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 1/9/2018
Florida Hospital Orlando
mi
from
Orlando, FL
Click here to add this to my saved trials
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  1/9/2018
University of Hawaii Cancer Center
mi
from
Honolulu, HI
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 1/9/2018
University of Hawaii Cancer Center
mi
from
Honolulu, HI
Click here to add this to my saved trials
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  1/9/2018
Saint Alphonsus Cancer Care Center-Boise
mi
from
Boise, ID
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 1/9/2018
Saint Alphonsus Cancer Care Center-Boise
mi
from
Boise, ID
Click here to add this to my saved trials
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  1/9/2018
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 1/9/2018
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials